Stephanie A Terezakis
Overview
Explore the profile of Stephanie A Terezakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu K, Salans M, Easwaran T, Phuong C, Yeo K, Elhalawani H, et al.
J Neurooncol
. 2025 Feb;
PMID: 39998722
Purpose: We characterized the association between photon radiation dose (< 59.4 versus ≥ 59.4 Gy) and outcomes in intracranial ependymoma. We also examined factors associated with survival after relapse. Methods:...
2.
Saifi O, Pinnix C, Ballas L, Kelsey C, Milgrom S, Terezakis S, et al.
Lancet Haematol
. 2024 Oct;
11(12):e951-e958.
PMID: 39362223
Contemporary lymphoma radiation target volumes that rely on post-systemic therapy imaging do not have standardised nomenclature. A forum of radiation oncology lymphoma leaders from the National Clinical Trials Network groups...
3.
Dimitrov M, Merkle S, Cao Q, Tryon R, Vercellotti G, Holtan S, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):1005.e1-1005.e17.
PMID: 39002862
Background: Dyskeratosis congenita/telomere biology disorders (DC/TBD) often manifest as bone marrow failure (BMF) or myelodysplastic syndrome (MDS). Allogeneic hematopoietic cell transplant (alloHCT) rescues hematologic complications, but radiation and alkylator-based conditioning...
4.
Liu K, Shaaban S, Chen J, Bagatell R, Lerman B, Catalano P, et al.
Radiother Oncol
. 2024 Jun;
198:110384.
PMID: 38880415
Background: Prognosis for patients with high-risk neuroblastoma (HR-NBL) is guarded despite aggressive therapy, and few studies have characterized outcomes after radiotherapy in relation to radiation treatment fields. Methods: Multi-institutional retrospective...
5.
Bergerud K, Berkseth M, Pardoll D, Ganguly S, Kleinberg L, Lawrence J, et al.
Int J Radiat Oncol Biol Phys
. 2023 Dec;
119(1):42-55.
PMID: 38042450
Radiation therapy (RT) has been a primary treatment modality in cancer for decades. Increasing evidence suggests that RT can induce an immunosuppressive shift via upregulation of cells such as tumor-associated...
6.
Greenlund L, Shanley R, Mulford K, Neil E, Lawrence J, Arnold S, et al.
Front Immunol
. 2023 Nov;
14:1284118.
PMID: 38022656
Introduction: Treatment for glioblastomas, aggressive and nearly uniformly fatal brain tumors, provide limited long-term success. Immunosuppression by myeloid cells in both the tumor microenvironment and systemic circulation are believed to...
7.
Shen C, Kry S, Buchsbaum J, Milano M, Inskip P, Ulin K, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
119(2):431-445.
PMID: 37565958
Purpose: Few reports describe the risks of late ocular toxicities after radiation therapy (RT) for childhood cancers despite their effect on quality of life. The Pediatric Normal Tissue Effects in...
8.
Hogan L, Brown P, Ji L, Xu X, Devidas M, Bhatla T, et al.
J Clin Oncol
. 2023 May;
41(25):4118-4129.
PMID: 37257143
Purpose: Blinatumomab, a bispecific T-cell engager immunotherapy, is efficacious in relapsed/refractory B-cell ALL (B-ALL) and has a favorable toxicity profile. One aim of the Children's Oncology Group AALL1331 study was...
9.
Liu K, Hammoudeh L, Haas-Kogan D, Terezakis S
Pediatr Blood Cancer
. 2022 Apr;
70(8):e29673.
PMID: 35373902
Little is known about the prevalence of pediatric radiation oncologists treating patients off study according to Children's Oncology Group (COG) trials before data are available regarding toxicity and efficacy of...
10.
Shen C, Terezakis S
Front Oncol
. 2021 Oct;
11:679701.
PMID: 34604027
Ongoing rapid advances in molecular diagnostics, precision imaging, and development of targeted therapies have resulted in a constantly evolving landscape for treatment of pediatric cancers. Radiotherapy remains a critical element...